Author

W. Shalata

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Immune-related adverse events and clinical outcomes in advanced non-small cell lung cancer: does more toxicity predict better outcomes?

Background Immune checkpoint inhibitors (ICIs) are a cornerstone of therapy for advanced non–small cell lung cancer (NSCLC). Elderly patients remain underrepresented in clinical trials, and the prognostic significance of immune-related adverse events (irAEs)—including their cumulative burden—across age groups is not fu...

A. Agbarya, N. S. Shrem, Asmah Miari et al. · Frontiers in Immunology · 0 citations

Open access Jul 2026

Real-world treatment patterns and outcomes of chemo-immunotherapy with or without radiotherapy in extensive-stage small cell lung cancer: the durvalumab expanded access cohort

In this multinational real-world cohort, outcomes with first-line chemo-immunotherapy were consistent with CASPIAN trial and the addition of cRT or sRT appeared feasible, safe, and associated with clinically meaningful survival improvements.

U. Janžič, W. Shalata, M. Unk et al. · Frontiers in Oncology · 0 citations